Inovio Pharma (INO) Misses Q2 EPS by 5c

Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.26), $0.05 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $4.95 million.

As of June 30, 2016, cash and cash equivalents and short-term investments were $134.5 million compared with $163.0 million as of December 31, 2015. There were 73.5 million shares outstanding and 81.2 million fully diluted.

The Company sold 119,400 shares of common stock at an average price of $11.12 per share, for net proceeds of $1.3 million, under the ATM common stock sales agreement implemented during the period.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Carlisle Cos. (CSL) Tops Q1 EPS by 91c, Beats on Revenue; Offers FY24 Outlook
• L3Harris Technologies (LHX) Tops Q1 EPS by 15c; raises guidance